Compartmental analysis of dopa decarboxylation in living brain from dynamic positron emission tomograms

Abstract

The trapping of decarboxylation products of radiolabelled dopa analogs in living human brain occurs as a function of the activity of dopa decarboxylase. This enzyme is now understood to regulate, with tyrosine hydroxylase, cerebral dopamine synthesis. Influx into brain of dopa decarboxylase substrates such as 6-[18F]fluorodopa and beta-[11C]dopa measured by positron emission tomography can be analyzed by solution of linear differential equations, assuming irreversible trapping of the decarboxylated products in brain. The isolation of specific physiological steps in the pathway for catecholamine synthesis requires compartmental modelling of the observed dynamic time-activity curves in plasma and in brain. The several approaches to the compartmental modelling of the kinetics of labelled substrates of dopa decarboxylase are now systematically and critically reviewed. Labelled catechols are extensively metabolized by hepatic catechol-O-methyltransferase yielding brain-penetrating metabolites. The assumption of a fixed blood-brain permeability ratio for O-methyl-6-[18F]fluorodopa or O-methyl-beta-[11C]dopa to the parent compounds eliminates several parameters from compartmental models. However, catechol-O-methyltransferase activity within brain remains a possible factor in underestimation of cerebral dopa decarboxylase activity. The O-methylation of labelled catechols is blocked with specific enzyme inhibitors, but dopa decarboxylase substrates derived from m-tyrosine may supplant the catechol tracers. The elimination from brain of decarboxylated tracer metabolites can be neglected without great prejudice to the estimation of dopa decarboxylase activity when tracer circulation is less than 60 minutes. However, elimination of dopamine metabolites from brain occurs at a rate close to that observed previously for metabolites of glucose labelled in the 6-position. This phenomenon can cause systematic underestimation of the rate of dopa decarboxylation in brain. The spillover of radioactivity due to the limited spatial resolution of tomographs also results in underestimation of dopa decarboxylase activity, but correction for partial volume effects is now possible. Estimates of dopa decarboxylase activity in human brain are increased several-fold by this correction. Abnormally low influx of dopa decarboxylase tracers in the basal ganglia is characteristic of Parkinson's disease and other movement disorders. Consistent with postmortem results, the impaired retention of labelled dopa is more pronounced in the putamen than in the caudate nucleus of patients with Parkinson's disease; this heterogeneity persists after correction for spillover. Current in vivo assays of dopa decarboxylase activity fail to discriminate clinically distinct stages in the progression of Parkinson's disease and are, by themselves, insufficient for differential diagnosis of Parkinson's disease and other subcortical movement disorders. However, potential new avenues for therapeutics can be tested by quantifying the rate of metabolism of exogenous dopa i...

Elevated [18F]Fluorodopamine Turnover in Brain of Patients with Schizophrenia: An [18F]Fluorodopa/Positron Emission Tomography Study

“…18 F]fluorodopamine results in underestimation of the true rate of FDOPA consumption in brain (Huang et al, 1991;Kuwabara et al, 1993;Cumming and Gjedde, 1998;Cumming et al, 2001;Kumakura et al, 2005). No compartmental PET model can accommodate the entire complexity of the catecholamine pathway; of necessity, the […”

“…These previous PET studies of schizophrenia, in analogy to the classic deoxyglucose model for measuring metabolic rate (Gjedde, 1981(Gjedde, , 1982Patlak et al, 1983;Patlak and Blasberg, 1985), have all assumed irreversible trapping of tracer metabolites formed in brain. However, this assumption was shown to be violated in one of the earliest presentations of the FDOPA compartmental analysis (Huang et al, 1991;Cumming and Gjedde, 1998), a violation resulting in underestimation of the true magnitude of FDOPA utilization in living brain ). To date, PET studies with DOPA decarboxylase substrates in patients with schizophrenia have used incomplete kinetic models, not accommodating the dynamics of the entire pathway for dopamine synthesis and turnover but incorrectly assuming irreversible trapping of the decarboxylated radiotracers.…”

PET Studies of Net Blood—Brain Clearance of FDOPA to Human Brain: Age-Dependent Decline of [18F]Fluorodopamine Storage Capacity

“…, and, in the present analysis, the plasma volume in the brain (V 0 ) was fixed at 0.05 mL/g (see Cumming and Gjedde (1998) for discussion and experimental support for these assumptions). In the constrained model, the magnitude of V e is first determined in the cerebellum, where the rate constant for decarboxylation of FDOPA (k 3 D ) is assumed to be zero.…”

Subchronic Haloperidol Downregulates Dopamine Synthesis Capacity in the Brain of Schizophrenic Patients In Vivo

“…This procedure has been shown to optimize the precision and accuracy of the estimation of k D 3 when the eventual elimination of decarboxylated metabolites from the brain is neglected (see Figure 3 in Cumming and Gjedde, 1998). For thalamus and cortical VOIs, 60 min emission recordings were used in order to improve the estimation of k D 3 in brain regions of low DDC activity.…”